Lynn D Hawkins

USPTO Granted Patents = 33 (Patent Applications = 7)

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 5.5

ph-index = 12

Forward Citations = 300(Granted Patents)

Location History:

Haverhill, MA (US) (1996 - 1998)
Concord, NH (US) (2007)
Andover, MA (US) (2011 - 2013)
Concord, MA (US) (2001 - 2021)

Company Filing History:

24 out of 529

Eisai R&d Management Co., Ltd.

patents

9 out of 677

Eisai Company, Limited

patents

Years Active: 1996-2021

Loading Chart...

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11130758 - Tetrahydropyrazolopyrimidine compounds (2021-09-28),

2. 10640500 - Tetrahydropyrazolopyrimidine compounds (2020-05-05),

3. RE47193 - Selectively substituted quinoline compounds (2019-01-07),

4. 10087174 - Selectively substituted quinoline compounds (2018-10-02),

5. 9850242 - Tetrahydropyrazolopyrimidine compounds (2017-12-26),

6. 9663486 - Selectively substituted quinoline compounds (2017-05-30),

7. 9446046 - Tetrahydropyrazolopyrimidine compounds (2016-09-20),

8. 9428495 - Selectively substituted quinoline compounds (2016-08-30),

9. 9126999 - Tetrahydropyrazolopyrimidine compounds (2015-09-08),

10. 8962857 - Compounds for preparing immunological adjuvant (2015-02-24),

11. 8754236 - Compounds for preparing immunological adjuvant (2014-06-17),

12. 8603482 - Compositions and methods for cancer immunotherapy (2013-12-10),

13. 8519170 - Compounds for preparing immunological adjuvant (2013-08-27),

14. 8198474 - Compounds for preparing immunological adjuvant (2012-06-12),

15. 8049023 - Reagents and methods for the beta-keto amide synthesis of a synthetic precursor to immunological adjuvant E6020 (2011-11-01),

Title: The Innovative Contributions of Lynn D. Hawkins

Introduction: Lynn D. Hawkins, a prominent inventor based in Concord, MA, has made significant strides in the field of pharmaceutical innovations. With an impressive portfolio of 33 patents, he is recognized for his contributions that enhance the understanding and treatment of complex medical conditions.

Latest Patents: Among his latest developments are the tetrahydropyrazolopyrimidine compounds. These compounds are particularly noteworthy as they serve as antagonists or inhibitors for Toll-like receptors 7 and/or 8. Their application extends to pharmaceutical compositions designed for the effective treatment of systemic lupus erythematosus (SLE) and lupus nephritis. The dual focus on both SLE and lupus nephritis demonstrates Hawkins' commitment to addressing critical health issues through innovative solutions.

Career Highlights: Lynn D. Hawkins has built a substantial career working with leading companies in the pharmaceutical industry. He has been affiliated with Eisai R&D Management Co., Ltd. and Eisai Company, Limited, where his research and innovations have had a direct impact on drug development and patient care.

Collaborations: Throughout his career, Hawkins has collaborated with esteemed professionals including Sally T. Ishizaka and Shawn Schiller. These collaborations not only highlight his ability to work effectively within teams but also emphasize the importance of collective expertise in advancing scientific research and innovation.

Conclusion: Lynn D. Hawkins is a distinguished inventor whose work continues to influence the pharmaceutical landscape. With his extensive patent portfolio and collaborative efforts, he plays a crucial role in developing therapies that aim to transform the lives of individuals suffering from systemic lupus erythematosus and lupus nephritis. His innovative spirit and dedication to research set a precedent for future advancements in medicine.

This text is generated by artificial intelligence and may not be accurate.